Chinese clinical contract research organization (CRO) dMed Biopharmaceutical has raised 354 million yuan ($50 million) in a Series B round led by Vivo Capital, according to a media statement.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
